What is the address of STEANN PHARMA?

The registered office of STEANN PHARMA is located at Hoogstraat 294 box C, 2570 Duffel.

Is STEANN PHARMA still active?

Yes. According to the CBE (29 October 2026) STEANN PHARMA is active, legal situation “Normale toestand”, started on 12 August 2016.

Is STEANN PHARMA registered on Peppol?

Yes, STEANN PHARMA is registered on the Peppol network with ID 0208:0660893761.

What is the enterprise number of STEANN PHARMA?

The enterprise number of STEANN PHARMA is BE0660893761.

When was STEANN PHARMA founded?

STEANN PHARMA was founded on 12 August 2016.

Who are the directors of STEANN PHARMA?

According to the 2025 annual accounts, the directors of STEANN PHARMA are: Anneleen De Swert.

Is STEANN PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 August 2016; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did STEANN PHARMA make in 2025?

STEANN PHARMA posted a profit after taxes of € 228,374 in financial year 2025.

What is the revenue of STEANN PHARMA?

As a small company, STEANN PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 178,213.

STEANN PHARMA (Private Limited) - Duffel - BE0660893761

Q: What does STEANN PHARMA do?

STEANN PHARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 12 August 2016, 1 establishment.

Dossier STEANN PHARMA, printed on 29 October 2026 from databakkes.be/en/0660893761/steann-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 31 % of short-term debt in 2025; threshold 65 %.
Figures corrected NBB

Corrected annual account filed for 2025.

Financials

Financial year 2025

STEANN PHARMA from Duffel, company number BE0660893761, closed financial year 2025 with a result of € 228,374 after tax. For that financial year STEANN PHARMA recorded a gross margin of € 178,213 and equity of € 958,845. Compared with financial year 2024, the result moved from € 119,291 to € 228,374. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on November 25, 2025.

What it is worth Growing

€ 958,845

▲ 31% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 228,374

▲ 91% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 29,209

▲ 114% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 883,845.

People and assets in 2025

Vehicles and equipment

€ 44,314

▼ 22% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 389,494

▼ 13% vs 2024

€ 57,725 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 884

▼ 49% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 7,368

▼ 30% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 173,090 Gross margin 2022: € 173,090 First fiscal year in the series	€ 195,860 Gross margin 2023: € 195,860 ▲ 13% vs 2022 (€ 173,090) Favourable step	€ 204,397 Gross margin 2024: € 204,397 ▲ 4% vs 2023 (€ 195,860) Favourable step	€ 178,213 Gross margin 2025: € 178,213 ▼ 13% vs 2024 (€ 204,397) Unfavourable step	▼ 13%
Profit after taxes	€ 108,508 Profit after taxes 2022: € 108,508 First fiscal year in the series	€ 122,945 Profit after taxes 2023: € 122,945 ▲ 13% vs 2022 (€ 108,508) Favourable step	€ 119,291 Profit after taxes 2024: € 119,291 ▼ 3% vs 2023 (€ 122,945) Unfavourable step	€ 228,374 Profit after taxes 2025: € 228,374 ▲ 91% vs 2024 (€ 119,291) Favourable step	▲ 91%
Equity	€ 488,235 Equity 2022: € 488,235 First fiscal year in the series	€ 611,179 Equity 2023: € 611,179 ▲ 25% vs 2022 (€ 488,235) Favourable step	€ 730,470 Equity 2024: € 730,470 ▲ 20% vs 2023 (€ 611,179) Favourable step	€ 958,845 Equity 2025: € 958,845 ▲ 31% vs 2024 (€ 730,470) Favourable step	▲ 31%
Total debts	€ 840,563 Total debts 2022: € 840,563 First fiscal year in the series	€ 1,038,182 Total debts 2023: € 1,038,182 ▲ 24% vs 2022 (€ 840,563) Unfavourable step	€ 762,251 Total debts 2024: € 762,251 ▼ 27% vs 2023 (€ 1,038,182) Favourable step	€ 1,144,693 Total debts 2025: € 1,144,693 ▲ 50% vs 2024 (€ 762,251) Unfavourable step	▲ 50%
Cash	€ 211,030 Cash 2022: € 211,030 First fiscal year in the series	€ 231,740 Cash 2023: € 231,740 ▲ 10% vs 2022 (€ 211,030) Favourable step	€ 13,647 Cash 2024: € 13,647 ▼ 94% vs 2023 (€ 231,740) Unfavourable step	€ 29,209 Cash 2025: € 29,209 ▲ 114% vs 2024 (€ 13,647) Favourable step	▲ 114%
Land & buildings	-	-	-	€ 398,773 Land & buildings 2025: € 398,773 First fiscal year in the series
Retained profit	€ 413,235 Retained profit 2022: € 413,235 First fiscal year in the series	€ 536,179 Retained profit 2023: € 536,179 ▲ 30% vs 2022 (€ 413,235) Favourable step	€ 655,470 Retained profit 2024: € 655,470 ▲ 22% vs 2023 (€ 536,179) Favourable step	€ 883,845 Retained profit 2025: € 883,845 ▲ 35% vs 2024 (€ 655,470) Favourable step	▲ 35%
Dividend	€ 170,000 Dividend 2022: € 170,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 170,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 558,078 Bank debt 2022: € 558,078 First fiscal year in the series	€ 502,639 Bank debt 2023: € 502,639 ▼ 10% vs 2022 (€ 558,078) Favourable step	€ 446,447 Bank debt 2024: € 446,447 ▼ 11% vs 2023 (€ 502,639) Favourable step	€ 389,494 Bank debt 2025: € 389,494 ▼ 13% vs 2024 (€ 446,447) Favourable step	▼ 13%
Balance sheet total	€ 1,328,798 Balance sheet total 2022: € 1,328,798 First fiscal year in the series	€ 1,649,361 Balance sheet total 2023: € 1,649,361 ▲ 24% vs 2022 (€ 1,328,798) Unchanged	€ 1,492,721 Balance sheet total 2024: € 1,492,721 ▼ 9% vs 2023 (€ 1,649,361) Unchanged	€ 2,103,538 Balance sheet total 2025: € 2,103,538 ▲ 41% vs 2024 (€ 1,492,721) Unchanged	▲ 41%

Key figures of STEANN PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to STEANN PHARMA?

What happened at STEANN PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Nov 25, 2025 Corrected annual accounts filed for financial year 2025. filed late Source: NBB ↗
Aug 12, 2016 New establishment in Duffel. KBO
Aug 12, 2016 Start of the company according to the CBE. KBO

In short

From € 108,508 profit in 2022 to € 228,374 profit in 2025.

Paid € 208,107 in corporate taxes since 2022.

Best year ever: 2025, with € 228,374 profit.

Paid out € 170,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Anneleen De Swert

STEANN PHARMA

ANW Soft 100%

Apotheek Lisp 100%

Behind STEANN PHARMA is Anneleen De Swert. It owns 100% of ANW Soft and 100% of Apotheek Lisp itself.

Directors

According to the 2025 annual accounts

Anneleen De Swert

Director

Also active at: A.N.W. - SOFT, Apotheek Lisp

Establishments

Establishment units

Physical locations of this company

Registered office

Hoogstraat 294 box C

2570 Duffel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

A.N.W. - SOFT same network

€ 4,063 gross margin · 2025

Advocatenkantoor Nick Paeleman

€ 173,780 gross margin · 2026

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0660.893.761

VAT number

BE 0660.893.761

Registered office

Hoogstraat 294 bus C, 2570 Duffel

Names & denominations

STEANN PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

12 August 2016

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

STEANN PHARMA

Warning lights

Financials

What happened to STEANN PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions